These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 28753865)

  • 1. Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.
    Lamy PJ; Allory Y; Gauchez AS; Asselain B; Beuzeboc P; de Cremoux P; Fontugne J; Georges A; Hennequin C; Lehmann-Che J; Massard C; Millet I; Murez T; Schlageter MH; Rouvière O; Kassab-Chahmi D; Rozet F; Descotes JL; Rébillard X
    Eur Urol Focus; 2018 Dec; 4(6):790-803. PubMed ID: 28753865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review.
    Olleik G; Kassouf W; Aprikian A; Hu J; Vanhuyse M; Cury F; Peacock S; Bonnevier E; Palenius E; Dragomir A
    J Natl Compr Canc Netw; 2018 Nov; 16(11):1340-1351. PubMed ID: 30442734
    [No Abstract]   [Full Text] [Related]  

  • 3. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
    Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
    Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
    Hendriks RJ; van Oort IM; Schalken JA
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 4Kscore Predicts the Grade and Stage of Prostate Cancer in the Radical Prostatectomy Specimen: Results from a Multi-institutional Prospective Trial.
    Punnen S; Nahar B; Prakash NS; Sjoberg DD; Zappala SM; Parekh DJ
    Eur Urol Focus; 2017 Feb; 3(1):94-99. PubMed ID: 28720374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
    Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
    Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
    Guazzoni G; Lazzeri M; Nava L; Lughezzani G; Larcher A; Scattoni V; Gadda GM; Bini V; Cestari A; Buffi NM; Freschi M; Rigatti P; Montorsi F
    Eur Urol; 2012 Mar; 61(3):455-66. PubMed ID: 22078333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biopsy Based Proteomic Assay Predicts Risk of Biochemical Recurrence after Radical Prostatectomy.
    Saad F; Latour M; Lattouf JB; Widmer H; Zorn KC; Mes-Masson AM; Ouellet V; Saad G; Prakash A; Choudhury S; Han G; Karakiewicz P; Richie JP
    J Urol; 2017 Apr; 197(4):1034-1040. PubMed ID: 27725152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of GEMCaP as a DNA Based Biomarker to Predict Prostate Cancer Recurrence after Radical Prostatectomy.
    Nguyen HG; Welty C; Lindquist K; Ngo V; Gilbert E; Bengtsson H; Magi-Galluzzi C; Jean-Gilles J; Yao J; Cooperberg M; Messing E; Klein EA; Carroll PR; Paris PL
    J Urol; 2018 Mar; 199(3):719-725. PubMed ID: 28941923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of surgical margins in prostate cancer.
    Sooriakumaran P; Dev HS; Skarecky D; Ahlering T
    J Surg Oncol; 2016 Mar; 113(3):310-5. PubMed ID: 27004601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
    Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
    Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy.
    Cantiello F; Russo GI; Ferro M; Cicione A; Cimino S; Favilla V; Perdonà S; Bottero D; Terracciano D; De Cobelli O; Morgia G; Damiano R
    Urol Oncol; 2015 Apr; 33(4):163.e15-23. PubMed ID: 25575715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apparent diffusion coefficient value is a strong predictor of unsuspected aggressiveness of prostate cancer before radical prostatectomy.
    Renard Penna R; Cancel-Tassin G; Comperat E; Mozer P; Léon P; Varinot J; Roupret M; Bitker MO; Lucidarme O; Cussenot O
    World J Urol; 2016 Oct; 34(10):1389-95. PubMed ID: 26902878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pathologic revision and Ki67 and ERG immunohistochemistry on predicting radical prostatectomy outcome in men initially on active surveillance.
    Bokhorst LP; Roobol MJ; Bangma CH; van Leenders GJ
    Prostate; 2017 Jul; 77(10):1137-1143. PubMed ID: 28543353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the Prostate Health Index for the Detection of Aggressive Prostate Cancer at Radical Prostatectomy.
    Mearini L; Nunzi E; Ferri C; Bellezza G; Lolli C; Porrozzi C; Porena M
    Urol Int; 2015; 95(4):390-9. PubMed ID: 25792149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
    Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
    J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.